Novel PROTACs for Targeted Protein Degradation: A Survey

www.surveyx.cn

Abstract

Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in targeted protein degradation (TPD), offering a novel approach to drug discovery and therapeutic interventions. Unlike conventional small molecule inhibitors that rely on occupancy-based inhibition, PROTACs utilize the ubiquitin-proteasome system (UPS) for selective protein degradation. This bifunctional strategy involves binding to both a target protein and an E3 ubiquitin ligase, facilitating ubiquitination and subsequent proteasomal degradation of the target protein. This survey paper explores recent advancements in TPD technologies, focusing on PROTACs, their mechanism of action, and their potential therapeutic applications. The paper is structured as follows: Section 2 provides an overview of TPD technologies, including the UPS and the historical development of PROTACs. Section 3 delves into the mechanism of action of PROTACs, focusing on their bifunctional nature, E3 ligase recruitment, and ternary complex formation. Section 4 examines factors influencing degradation efficacy and discusses the importance of structural optimization. Section 5 compares PROTACs with traditional small molecule inhibitors, highlighting their advantages and potential to target 'undruggable' proteins. Section 6 explores current applications of PROTACs in therapeutic areas such as cancer and neurodegenerative diseases, along with emerging trends and future directions in PROTAC research. Finally, Section 7 concludes by emphasizing the transformative potential of PROTACs in drug discovery and targeted therapy while outlining challenges and opportunities for future research.

1 Introduction

1.1 Introduction

Proteolysis Targeting Chimeras (PROTACs) signify a transformative approach in targeted protein degradation (TPD), offering a novel strategy for drug discovery and therapeutic interventions. Unlike traditional small molecule inhibitors that depend on occupancy-based mechanisms, PROTACs utilize the ubiquitin-proteasome system (UPS) to selectively degrade target proteins. This bifunctional strategy involves simultaneous binding to both a target protein and an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent proteasomal degradation of the target protein. The capacity of PROTACs to target proteins previously deemed 'undruggable' by conventional methods significantly broadens the therapeutic landscape [1].

The UPS plays a crucial role in maintaining protein homeostasis by degrading misfolded or damaged proteins, with its dysregulation linked to various malignancies, thus highlighting its therapeutic potential [2]. By harnessing this system, PROTACs not only deplete pathogenic proteins but also mitigate drug resistance issues associated with traditional inhibitors [3]. This survey encapsulates recent advancements in TPD technologies, particularly PROTACs, and their prospective applications in drug discovery and disease treatment [1].



Figure 1: chapter structure

The structure of this paper is organized as follows: Section 2 provides background on targeted protein degradation, detailing the UPS, the historical evolution of PROTACs, and an overview of various TPD technologies. Section 3 explores the mechanism of action of PROTACs, focusing on their bifunctional nature, E3 ligase recruitment, and ternary complex formation. Section 4 examines factors influencing PROTAC degradation efficacy, discussing structural optimization and recent advancements in their design and synthesis. Section 5 presents a comprehensive comparison between PROTACs and traditional small molecule inhibitors, emphasizing the unique advantages of PROTACs in targeting 'undruggable' proteins through selective degradation mechanisms. This section also reviews specific case studies demonstrating the superior efficacy of PROTACs in overcoming drug resistance and reducing toxicity, underscoring their potential as a transformative approach in therapeutic development [4, 1, 5]. Section 6 investigates current applications of PROTACs in therapeutic areas such as cancer and neurodegenerative diseases, alongside emerging trends and future directions in PROTAC research. Finally, Section 7 concludes by emphasizing the transformative potential of PROTACs in drug discovery and targeted therapy while addressing the challenges and opportunities for future research in this field.The following sections are organized as shown in Figure 1.

2 Background on Targeted Protein Degradation

2.1 Ubiquitin-Proteasome System

The ubiquitin-proteasome system (UPS) is crucial for the degradation of oxidized, damaged, or misfolded proteins in eukaryotic cells, maintaining protein homeostasis and regulating cellular processes such as growth and apoptosis. Proteins are tagged with polyubiquitin chains and subsequently degraded by the 26S proteasome complex. Dysregulation of the UPS is linked to various malignancies, making it a target for cancer therapies, with proteasome inhibitors like Bortezomib approved for hematological cancers [6, 2].

Central to the UPS are E3 ubiquitin ligases, which confer substrate specificity by transferring ubiquitin from E2 enzymes to target proteins. Despite the existence of over 600 E3 ligases, research has focused on a limited few, presenting an opportunity to explore other ligases [7]. The UPS includes E1 activating enzymes, E2 conjugating enzymes, and deubiquitinases (DUBs), which modulate protein degradation pathways and are potential therapeutic targets in cancer biology [2].

Ubiquitinated proteins may be directed towards proteasomal degradation or autophagy, influenced by the type of ubiquitination and modulated by deubiquitinating enzymes and post-translational modifications [8]. The interplay between the UPS and autophagy is significant, as ubiquitin signals degradation via both pathways [9]. In cancer, the UPS regulates oncogenic protein stability, making it a viable therapeutic target [4]. Its interactions with viral proteins affect immune responses and viral replication, underscoring its role in disease pathogenesis and novel therapy development. Together with lysosomal systems, the UPS forms a comprehensive framework for targeted protein degradation technologies, emphasizing their complementary roles in maintaining cellular protein balance [10].

2.2 Historical Development of PROTACs

Proteolysis Targeting Chimeras (PROTACs) emerged in the early 2000s as a significant advancement in targeted protein degradation, utilizing the UPS to modulate protein levels. Initial PROTACs employed peptide-based linkers to recruit E3 ubiquitin ligases, demonstrating the feasibility of this approach [1]. However, challenges with cell permeability and stability limited their therapeutic application.

The transition to small molecule linkers marked a critical advancement, enhancing pharmacokinetic properties and expanding the range of targetable proteins, including those previously considered 'undruggable', particularly in oncology [11]. A key challenge in PROTAC development is the limited diversity of E3 ligases for recruitment, constraining therapeutic potential. Efforts continue to expand the E3 ligase repertoire and enhance degradation of difficult-to-target proteins [12]. The rational design of PROTACs is further complicated by an incomplete understanding of their selectivity and target recruitment mechanisms, necessitating continued research [1].

The historical trajectory of PROTACs illustrates their transformative potential in drug discovery, offering innovative solutions to overcome drug resistance and target complex disease pathways. As research progresses, integrating PROTACs into therapeutic strategies holds promise for unlocking new avenues in treating diseases through targeted protein degradation [1].

2.3 Overview of Targeted Protein Degradation Technologies

Advancements in targeted protein degradation have led to various technologies aimed at modulating protein levels within cells. PROTACs have emerged as a cornerstone, utilizing the UPS to degrade proteins otherwise difficult to target with conventional inhibitors. They function by forming a ternary complex that recruits an E3 ubiquitin ligase to the target protein, facilitating its ubiquitination and subsequent degradation [13].

In addition to PROTACs, molecular glues stabilize protein-protein interactions, often leading to degradation of one partner, with immunomodulatory imide drugs (IMiDs) exemplifying this approach [14, 15]. Lysosome-targeting chimeras (LYTACs) expand protein degradation scope by binding cell-surface lysosome-shuttling receptors, directing extracellular proteins to lysosomes [16]. Engineered systems like the C.e. AIDv2 System leverage auxin-inducible degradation for specific protein degradation, showcasing the field's diversity [17].

The integration of autophagic pathways further enriches targeted protein degradation strategies, with ubiquitin linkages directing proteins towards autophagic or proteasomal degradation, highlighting pathway interplay [9]. Advances in PROTAC linker design, including click chemistry and photo-switchable PROTACs, have improved degradation specificity and controllability [18].

The diverse array of targeted protein degradation (TPD) technologies, encompassing PROTACs, molecular glues, LYTACs, and autophagy-targeting strategies, provides a robust toolkit for drug discovery. These approaches leverage cellular protein degradation machinery, such as the UPS and lysosomal pathways, to modulate protein levels effectively, presenting new therapeutic avenues, particularly in cancer treatment where traditional methods often fall short [19, 4, 10, 11, 1]. These technologies hold the potential to target previously undruggable proteins, offering promising strategies for complex disease treatment.

3 Mechanism of Action of PROTACs

Proteolysis Targeting Chimeras (PROTACs) facilitate targeted protein degradation through sophisticated molecular interactions. Their bifunctional structure allows simultaneous binding to a specific protein of interest and an E3 ubiquitin ligase, forming a ternary complex that enhances degradation specificity. This dual engagement is crucial for ubiquitination and subsequent degradation via the 26S proteasome, showcasing PROTACs' potential in therapeutic applications. Figure 2 illustrates the hierarchical structure of the mechanism of action of PROTACs, highlighting their bifunctional nature and the formation of ternary complexes. This figure details the bifunctional architecture, adaptability in E3 ligase recruitment, and computational advances in PROTAC design, as well as the role, design versatility, and functional importance of ternary complex formation in targeted protein degradation.



Figure 2: This figure illustrates the hierarchical structure of the mechanism of action of PROTACs, highlighting their bifunctional nature and the formation of ternary complexes. It details the bifunctional architecture, adaptability in E3 ligase recruitment, and computational advances in PROTAC design, as well as the role, design versatility, and functional importance of ternary complex formation in targeted protein degradation.

3.1 Bifunctional Nature and E3 Ligase Recruitment

The bifunctional architecture of PROTACs is central to selective protein degradation, involving two moieties: one targeting the protein of interest and another recruiting an E3 ubiquitin ligase. This results in a ternary complex that marks the target protein for proteasomal degradation, exploiting the ubiquitin-proteasome system (UPS) to eliminate disease-relevant proteins [4, 13, 1, 5]. PROTACs' adaptability enables recruitment of diverse E3 ligases, expanding the range of targetable proteins, including those deemed 'undruggable'. The discovery of alkenyl oxindoles, for instance, facilitates recruitment of the CRL4 DCAF11 E3 ligase complex, enhancing degradation efficiency [12].

As illustrated in Figure 3, the bifunctional nature and recruitment versatility of E3 ligases by PROTACs and related molecules are emphasized, showcasing their adaptability and the role of alkenyl oxindoles in enhancing degradation, alongside the recruitment capabilities of immunomodulatory imide drugs (IMiDs). Parallel to PROTACs, bifunctional molecules like IMiDs recruit proteins such as FAM83F and CK1 to the CRBN E3 ligase complex for degradation [15]. This versatility underscores the potential of bifunctional molecules in orchestrating targeted protein degradation. Recent computational advances, such as PepMLM, leverage deep learning to generate peptide binders from target protein sequences without structural data, refining PROTAC design and enhancing E3 ligase recruitment specificity [14].



Figure 3: This figure illustrates the bifunctional nature and recruitment versatility of E3 ligases by PROTACs and related molecules, emphasizing their adaptability, the role of alkenyl oxindoles in enhancing degradation, and IMiDs' recruitment capabilities.

3.2 Ternary Complex Formation

Ternary complex formation is pivotal in PROTAC action, dictating specificity and efficacy in targeted protein degradation. This complex involves simultaneous binding of a PROTAC to a target protein and an E3 ubiquitin ligase, facilitating ubiquitination and degradation [11]. Structural analyses, such as those of the PROTAC MZ1 with E3 ligase VHL and Brd4 BD2, elucidate the intermolecular interactions critical for selective degradation [13].

Electrophilic PROTACs, which link target protein ligands to reactive electrophilic fragments, exemplify design versatility in stable ternary complex formation with various ligases [20]. Specific PROTACs like A1874 illustrate the importance of precise ternary complex formation for selective degradation, promoting BRD4 ubiquitination while sparing non-target proteins like p53, thereby minimizing off-target effects [21].

Ternary complex formation is fundamental to PROTAC functionality, facilitating targeted recruitment of E3 ubiquitin ligases and ensuring selective degradation by the 26S proteasome. Recent studies reveal cooperative interactions within this complex, highlighting how precise PROTAC design enhances degradation efficiency and selectivity [13, 1, 5, 20]. This process is a cornerstone of the PROTAC strategy, offering a powerful approach to modulate protein levels and broaden the scope of druggable targets.

4 Degradation Efficacy and Structural Optimization

4.1 Factors Influencing Degradation Efficacy

The efficacy of Proteolysis Targeting Chimeras (PROTACs) in protein degradation is contingent upon several key factors, including the selection of E3 ligase recruiters, ligand structural adaptability, and pharmacokinetic properties. Table 1 provides a comprehensive comparison of different protein degradation methods, emphasizing these critical factors of E3 ligase selection, ligand adaptability, and degradation control that influence the efficacy of these technologies. As illustrated in Figure 4, these primary factors significantly influence the outcomes of PROTAC-mediated protein degradation. The limited availability of E3 ligases constrains the range of proteins that can be targeted, highlighting the need for an expanded E3 ligase repertoire to enhance PROTAC applicability [12, 1]. Ligand

Method Name	E3 Ligase Selection	Ligand Adaptability	Degradation Control
PROTACs[11]	E3 Ligase Recruiters	Ternary Complex Formation	Engineered Systems Advancements
AIDv2[17]	Mutant AT Tir1	5-Ph-IAA Analog	Engineered Auxin-inducible
PepMLM[14]	-	-	Computational Advancements
IMiD-FAM83F[15]	Crbn E3 Ligase	Imids Binding	Engineered Systems

Table 1: Comparison of various protein degradation methods focusing on E3 ligase selection, ligand adaptability, and degradation control mechanisms. This table highlights the distinct approaches and technological advancements employed by PROTACs, AIDv2, PepMLM, and IMiD-FAM83F in enhancing protein degradation efficacy.

adaptability is crucial, as flexible binding interactions enable various conformations, facilitating selective targeting and stable ternary complex formation essential for effective ubiquitination and degradation [11].

Engineered systems, such as the auxin-inducible degradation system, offer precise control over protein degradation, enhancing specificity and reducing off-target effects at lower concentrations of auxin analogs [17]. Computational advancements, including PepMLM, leverage protein language modeling to generate binders for 'undruggable' proteins, broadening the spectrum of targetable proteins [14]. The selective degradation of protein isoforms, such as FAM83F by IMiDs, without affecting other FAM83 proteins, underscores the therapeutic promise of PROTACs [15]. However, the complexity of ubiquitin-proteasome system regulation and cancer cells' modulation of E3 ligase expression present significant challenges for PROTAC application in oncology.

The strategic selection of E3 ligase recruiters, ligand adaptability, and precise control of degradation processes collectively underscore PROTACs' potential as transformative agents for previously undruggable epigenetic targets [22].



Figure 4: This figure illustrates the primary factors influencing the efficacy of PROTAC-mediated protein degradation, emphasizing the roles of E3 ligase selection, ligand adaptability, and pharmacokinetic properties in enhancing degradation outcomes.

4.2 Structural Optimization

Optimizing the structure of PROTACs is essential for enhancing specificity and potency, influencing their ability to selectively degrade target proteins while minimizing off-target effects. A crucial aspect is the design of linkers connecting the target protein ligand to the E3 ubiquitin ligase ligand. The length, flexibility, and chemical composition of these linkers significantly impact the stability and formation of the ternary complex, thereby affecting degradation efficacy [18].

Activity-based protein profiling (ABPP) has facilitated the discovery of cysteine-reactive small molecules as ligands for E3 ligases like RNF4, broadening the spectrum of targetable proteins and enhancing specificity [23]. Insights into the molecular interactions governing protein binding and degradation, such as those revealed by nimbolide's mechanism, inform the refinement of PROTAC designs to enhance binding affinity and selectivity [24].

The strategic design of linkers and identification of reactive sites on E3 ligases are crucial for optimizing PROTAC structural characteristics, significantly influencing efficacy and selectivity. These advancements bolster the therapeutic potential of PROTACs and extend their applicability to a

broader range of previously undruggable targets, presenting promising avenues for drug discovery and targeted therapy [13, 1, 25].

4.3 Advancements in Design and Synthesis

Recent advancements in PROTAC design and synthesis have significantly enhanced their therapeutic potential, focusing on optimizing pharmacokinetic properties, specificity, and efficacy. Novel linker strategies, including photo-switchable PROTACs, enable controlled protein degradation with spatial and temporal precision, reducing off-target effects and improving therapeutic outcomes [18].

The integration of machine learning (ML) techniques into PROTAC development has streamlined the design process. Graph-based deep generative models have increased the proportion of active designs from 53% to 82% through reinforcement learning, significantly enhancing predicted activity [26]. ML has also deepened understanding of PROTAC mechanisms, paving the way for more effective therapeutic agents [25].

Light-controllable PROTACs (pc-PROTACs) represent an innovative advancement, allowing precise regulation of protein degradation across various biological contexts. Ongoing research aims to optimize pc-PROTAC synthesis and assess their therapeutic potential, enhancing their applicability in targeted therapies [27].

Exploration of new E3 ligase recruiters, such as alkenyl oxindoles, has expanded the range of targetable proteins, opening new avenues for cancer therapy. Future research is directed toward optimizing PROTAC design to engage additional E3 ligases, broadening their therapeutic potential across various cancer types [12]. The use of MDM2-recruiting PROTACs, such as A1874, has demonstrated superior antiproliferative activity compared to traditional methods, underscoring the promise of these novel strategies in cancer treatment [21].

5 Comparison with Traditional Small Molecule Inhibitors

5.1 Advantages Over Traditional Inhibitors

Proteolysis Targeting Chimeras (PROTACs) offer distinct advantages over traditional small molecule inhibitors by leveraging the ubiquitin-proteasome system for targeted protein degradation. Unlike conventional inhibitors, which often require high systemic concentrations to achieve effective inhibition and may lead to undesirable side effects [28], PROTACs can catalytically degrade target proteins at lower concentrations, reducing the necessity for sustained high drug levels. This approach exploits the plasticity of protein interactions, allowing for the design of selective degraders that target specific proteins while minimizing off-target effects [29]. Consequently, PROTACs can address the limitations of traditional inhibitors by targeting previously 'undruggable' proteins [11].

PROTACs also exhibit superior efficacy in overcoming drug resistance, a common challenge with traditional inhibitors. By promoting target protein degradation, PROTACs effectively address both canonical and non-canonical functions, offering a comprehensive strategy for modulating disease pathways [22]. This is particularly evident in targeting proteins involved in critical signaling pathways, such as the Wnt signaling pathway, where PROTACs demonstrate specificity in degrading FAM83F, providing a novel mechanism to modulate these pathways compared to traditional inhibitors [15]. Recent advancements in linker design and innovative strategies further enhance PROTACs' potential for targeted protein degradation, highlighting their versatility and efficacy in therapeutic applications [18]. The transition from inhibiting protein activity to degrading target proteins represents a paradigm shift in drug discovery, offering promising solutions to challenges historically limiting the therapeutic potential of traditional inhibitors [1].

5.2 Targeting 'Undruggable' Proteins

PROTACs represent a transformative approach in drug discovery, particularly for targeting proteins previously considered 'undruggable', such as transcription factors lacking well-defined binding pockets due to structural disorder, which complicates targeting by conventional inhibitors [16]. PROTACs overcome these limitations by utilizing the ubiquitin-proteasome system to degrade such proteins, thereby extending the range of targetable proteins beyond traditional pharmacological methods. The development of HL435 exemplifies PROTACs' efficacy in targeting 'undruggable'

proteins, effectively degrading BRD4 through the CRL4 DCAF11 E3 ligase complex [12]. This strategy underscores PROTACs' versatility in engaging previously inaccessible targets and modulating critical biological pathways implicated in disease progression.

The ability of PROTACs to target 'undruggable' proteins has significant implications for overcoming drug resistance, a pervasive challenge in cancer therapy and other diseases. By inducing target protein degradation, PROTACs can counteract compensatory mechanisms that often lead to resistance with traditional inhibitors. This is particularly relevant for transcription factors and other regulatory proteins that play pivotal roles in cellular signaling and gene expression, where PROTACs offer a novel means to disrupt aberrant pathways driving disease [16].

5.3 Case Studies

Case studies involving PROTACs illustrate their superior efficacy as transformative therapeutic agents. A notable example is the PROTAC ARV-110, targeting the androgen receptor (AR), a critical driver in prostate cancer. Developed by Arvinas, ARV-110 has demonstrated promising results in clinical trials, effectively reducing AR levels and exhibiting significant anti-tumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) [30]. This case highlights PROTACs' capability to target and degrade proteins crucial for disease progression, offering potential therapeutic benefits in treatment-resistant cancers.

Another significant case study involves the PROTAC DT2216, targeting the B-cell lymphoma 2 (BCL-2) family of proteins, key regulators of apoptosis implicated in various cancers. DT2216 has shown remarkable efficacy in preclinical models, selectively degrading BCL-XL while sparing platelets, thereby reducing the risk of thrombocytopenia, a common side effect associated with BCL-2 inhibitors [12]. This underscores PROTACs' precision and specificity in targeting proteins within complex cellular pathways, minimizing off-target effects and enhancing therapeutic outcomes.

The development of PROTACs targeting the bromodomain and extra-terminal (BET) family of proteins, such as BRD4, further exemplifies their efficacy. The PROTAC MZ1, which targets BRD4, efficiently degrades the protein and inhibits tumor growth across various cancer models, showcasing PROTACs' potential to address 'undruggable' targets [13]. This case study highlights PROTACs' versatility in modulating epigenetic regulators and disrupting oncogenic transcriptional programs.

6 Applications and Future Directions

6.1 Current Therapeutic Applications

Proteolysis Targeting Chimeras (PROTACs) are revolutionizing oncology by effectively targeting proteins deemed 'undruggable', such as those implicated in prostate and breast cancer. ARV-110 and ARV-471, currently in phase I clinical trials, exemplify this by degrading proteins critical to cancer progression, thereby circumventing traditional drug resistance [11]. PROTACs operate by recruiting E3 ubiquitin ligases to degrade target proteins, emphasizing the need to expand the repertoire of E3 ligases to enhance therapeutic efficacy. Recent innovations, including molecular glues and targeted degradation technologies, have shown potential in addressing challenging targets like transcription factors and fusion proteins [19].

Beyond oncology, PROTACs are being explored for various diseases. Nimbolide, a terpenoid from the Neem tree, modifies a cysteine in the E3 ligase RNF114, disrupting substrate recognition and stabilizing tumor suppressors such as p21, thereby inhibiting breast cancer cell proliferation [31, 32, 11, 24]. Compounds like A1874, which degrade BRD4 while stabilizing p53, further illustrate PROTACs' dual therapeutic potential. Innovations such as photo-controllable PROTACs (pc-PROTACs) allow for light-activated protein degradation, offering insights into protein dynamics and advancing drug discovery [19, 4, 20, 27, 1].

The ongoing development of PROTACs, with multiple candidates in clinical trials, highlights their potential to revolutionize therapeutic strategies across medical fields. By utilizing the ubiquitin-proteasome system to selectively degrade disease-related proteins, PROTACs offer solutions for complex diseases that traditional inhibitors struggle to address, with benefits including catalytic action, reduced dosing frequency, enhanced selectivity, and the ability to overcome drug resistance [4, 5, 25, 18].

6.2 Expansion of E3 Ligase Toolbox

Enhancing the E3 ligase toolbox is crucial for expanding targetable proteins and improving degradation specificity in PROTAC development. Identifying novel E3 ligases is essential for optimizing the pharmacological profiles and efficacy of PROTACs [32]. The current reliance on a limited subset of E3 ligases restricts PROTAC potential, necessitating a broader repertoire capable of degrading diverse protein targets.

Research into novel structures, such as Selective Estrogen Receptor Degraders (SERDs), exemplifies efforts to improve degradation strategies by identifying ligases with unique substrate specificities [32]. Targeting writer and eraser enzymes associated with post-translational modifications (PTMs) further emphasizes the importance of expanding the E3 ligase toolbox, as these enzymes influence protein stability and function, offering new therapeutic intervention opportunities [8].

6.3 Emerging Trends and Innovations

The field of PROTACs is rapidly evolving, driven by research focused on enhancing specificity, efficacy, and the diversity of targetable proteins. Designed for targeted protein degradation, PROTACs are being developed to address approximately 50 clinically validated proteins, many of which are critical oncoproteins. Recent studies highlight their ability to surpass the limitations of traditional inhibitors, offering improved therapeutic efficacy and reduced toxicity, while addressing drug resistance. Efforts are ongoing to optimize PROTAC design, expand E3 ligase options, and explore applications across various diseases, including hematological malignancies and epigenetic targets [4, 22, 1, 5].

Optimizing PROTAC design through linker chemistry is a significant trend, as linker length and flexibility affect ternary complex stability and degradation efficiency. Additionally, exploring tissue-specific E3 ligases aims to enhance PROTAC selectivity and targeted action, facilitating localized protein degradation to minimize off-target effects [28].

Machine learning (ML) is emerging as a transformative tool in PROTAC research, enabling the rational design of these molecules. By integrating three-dimensional structural information with sophisticated algorithms, ML models can predict degradation efficiency in targeted protein degradation (TPD) strategies, enhancing PROTAC design and optimization [33, 25]. ML accelerates PROTAC development and enables exploration of novel linker chemistries and potential new targets and E3 ligases.

The development of nutlin-based PROTACs and their application in diverse cancer models exemplify ongoing optimization efforts for enhanced efficacy. These PROTACs have shown promising preclinical results, indicating their potential as effective cancer therapeutics [21]. Continued research into their design and application is essential for broadening their therapeutic utility across various cancer types.

Furthermore, exploring specific inhibitors for E3 ligases and combination therapies targeting multiple pathways represents promising strategies for enhancing the apoptotic response in cancer cells [7]. The ability to selectively target and degrade 'undruggable' proteins paves the way for addressing drug resistance and modulating complex disease pathways [22].

Future research should prioritize optimizing linker design and exploring additional E3 ligases to improve PROTAC selectivity and efficacy. Integrating PepMLM with high-throughput screening methods and retraining models with modification-aware embeddings can enhance specificity [14]. Expanding the E3 ligase toolbox and improving cell permeability are crucial for broadening PROTAC applications beyond cancer [5]. Additionally, further optimization of systems like AIDv2 could enhance PROTAC capabilities across a wider range of proteins [17].

7 Conclusion

Proteolysis Targeting Chimeras (PROTACs) have emerged as a pivotal innovation in the realm of drug discovery and targeted therapies, offering a unique capability to degrade proteins previously considered 'undruggable'. By harnessing the ubiquitin-proteasome system, PROTACs utilize a bifunctional approach to achieve selective protein degradation, thus expanding the horizons of therapeutic interventions. Recent developments, such as the introduction of novel PROTAC structures,

exemplify the continuous evolution of strategies aimed at exploiting targeted protein degradation to address complex disease mechanisms.

The integration of machine learning into the design of PROTACs signifies a crucial advancement, facilitating the optimization of multiple design parameters and overcoming specific challenges. This computational approach is set to accelerate the creation of potent PROTACs, enhancing their therapeutic impact. Additionally, early assessment of degradation kinetics is essential for understanding the mechanisms of action, thereby accelerating therapeutic progress.

Nevertheless, the landscape of PROTACs is not without challenges. Ongoing innovation in the field of targeted protein degradation, including the exploration of lysosomal-mediated approaches, is essential to address the limitations associated with ubiquitin-proteasome system-based methods. Further, the refinement of nimbolide derivatives to improve selectivity and effectiveness, as well as the exploration of alternative E3 ligases, holds promise for broadening the scope of therapeutic applications.

The study of Selective Estrogen Receptor Degraders (SERDs) underscores the importance of elucidating their mechanisms and optimizing drug design to enhance efficacy and counteract resistance. Moreover, the potential of IMiD-induced degradation to modulate Wnt signaling highlights the critical role of targeted protein degradation in advancing drug discovery and therapeutic development.

References

[1] Stacey-Lynn Paiva and Craig M Crews. Targeted protein degradation: elements of protac design. *Current opinion in chemical biology*, 50:111–119, 2019.

[2] Chee Wai Fhu and Azhar Ali. Dysregulation of the ubiquitin proteasome system in human malignancies: a window for therapeutic intervention. *Cancers*, 13(7):1513, 2021.

[3] Behnam Nabet, Justin M Roberts, Dennis L Buckley, Joshiawa Paulk, Shiva Dastjerdi, Annan Yang, Alan L Leggett, Michael A Erb, Matthew A Lawlor, Amanda Souza, et al. The dtag system for immediate and target-specific protein degradation. *Nature chemical biology*, 14(5):431–441, 2018.

[4] Xin Li and Yongcheng Song. Proteolysis-targeting chimera (protac) for targeted protein degradation and cancer therapy. *Journal of hematology & oncology*, 13:1–14, 2020.

[5] Ke Li and Craig M Crews. Protacs: past, present and future. *Chemical Society Reviews*, 51(12):5214–5236, 2022.

[6] Jinyoung Park, Jinhong Cho, and Eun Joo Song. Ubiquitin–proteasome system (ups) as a target for anticancer treatment. *Archives of pharmacal research*, 43(11):1144–1161, 2020.

[7] Ruqaia Abbas and Sarit Larisch. Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system. *Cells*, 10(12):3465, 2021.

[8] Ji Min Lee, Henrik M Hammarén, Mikhail M Savitski, and Sung Hee Baek. Control of protein stability by post-translational modifications. *Nature Communications*, 14(1):201, 2023.

[9] Nur Mehpare Kocaturk and Devrim Gozuacik. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. *Frontiers in cell and developmental biology*, 6:128, 2018.

[10] Yu Xue, Andrew A Bolinger, and Jia Zhou. Novel approaches to targeted protein degradation technologies in drug discovery. *Expert opinion on drug discovery*, 18(4):467–483, 2023.

[11] Brandon Dale, Meng Cheng, Kwang-Su Park, H Ümit Kaniskan, Yue Xiong, and Jian Jin. Advancing targeted protein degradation for cancer therapy. *Nature Reviews Cancer*, 21(10):638–654, 2021.

[12] Ying Wang, Tianzi Wei, Man Zhao, Aima Huang, Fan Sun, Lu Chen, Risheng Lin, Yubao Xie, Ming Zhang, Shiyu Xu, et al. Alkenyl oxindole is a novel protac moiety that recruits the crl4dcaf11 e3 ubiquitin ligase complex for targeted protein degradation. *Plos Biology*, 22(5):e3002550, 2024.

[13] Morgan S Gadd, Andrea Testa, Xavier Lucas, Kwok-Ho Chan, Wenzhang Chen, Douglas J Lamont, Michael Zengerle, and Alessio Ciulli. Structural basis of protac cooperative recognition for selective protein degradation. *Nature chemical biology*, 13(5):514–521, 2017.

[14] Tianlai Chen, Madeleine Dumas, Rio Watson, Sophia Vincoff, Christina Peng, Lin Zhao, Lauren Hong, Sarah Pertsemlidis, Mayumi Shaepers-Cheu, Tian Zi Wang, Divya Srijay, Connor Monticello, Pranay Vure, Rishab Pulugurta, Kseniia Kholina, Shrey Goel, Matthew P. DeLisa, Ray Truant, Hector C. Aguilar, and Pranam Chatterjee. Pepmlm: Target sequence-conditioned generation of therapeutic peptide binders via span masked language modeling, 2024.

[15] Karen Dunbar, Thomas J Macartney, and Gopal P Sapkota. Imids induce fam83f degradation via an interaction with ck1α to attenuate wnt signalling. *Life Science Alliance*, 4(2), 2021.

[16] Madeleine J Henley and Angela N Koehler. Advances in targeting 'undruggable'transcription factors with small molecules. *Nature Reviews Drug Discovery*, 20(9):669–688, 2021.

[17] Kelly Hills-Muckey, Michael AQ Martinez, Natalia Stec, Shilpa Hebbar, Joanne Saldanha, Taylor N Medwig-Kinney, Frances EQ Moore, Maria Ivanova, Ana Morao, Jordan D Ward, et al. An engineered, orthogonal auxin analog/at tir1 (f79g) pairing improves both specificity and efficacy of the auxin degradation system in caenorhabditis elegans. *Genetics*, 220(2):iyab174, 2022.

[18] Almaz Zagidullin, Vasili Milyukov, Albert Rizvanov, and Emil Bulatov. Novel approaches for the rational design of protac linkers. *Exploration of Targeted Anti-tumor Therapy*, 1(5):381, 2020.

[19] Lin Zhao, Jia Zhao, Kunhong Zhong, Aiping Tong, and Da Jia. Targeted protein degradation: mechanisms, strategies and application. *Signal transduction and targeted therapy*, 7(1):113, 2022.

[20] Xiaoyu Zhang, Vincent M Crowley, Thomas G Wucherpfennig, Melissa M Dix, and Benjamin F Cravatt. Electrophilic protacs that degrade nuclear proteins by engaging dcaf16. *Nature chemical biology*, 15(7):737–746, 2019.

[21] John Hines, Schan Lartigue, Hanqing Dong, Yimin Qian, and Craig M Crews. Mdm2-recruiting protac offers superior, synergistic antiproliferative activity via simultaneous degradation of brd4 and stabilization of p53. *Cancer research*, 79(1):251–262, 2019.

[22] Md Kabir, Xufen Yu, H Ümit Kaniskan, and Jian Jin. Chemically induced degradation of epigenetic targets. *Chemical Society Reviews*, 52(13):4313–4342, 2023.

[23] <div style="text-align: center;".

[24] Jessica N Spradlin, Xirui Hu, Carl C Ward, Scott M Brittain, Michael D Jones, Lisha Ou, Milton To, Andrew Proudfoot, Elizabeth Ornelas, Mikias Woldegiorgis, et al. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. *Nature chemical biology*, 15(7):747–755, 2019.

[25] Yossra Gharbi and Rocío Mercado. A comprehensive review of emerging approaches in machine learning for de novo protac design, 2024.

[26] Divya Nori, Connor W. Coley, and Rocío Mercado. De novo protac design using graph-based deep generative models, 2022.

[27] Gang Xue, Kun Wang, Danli Zhou, Hanbing Zhong, and Zhengying Pan. Light-induced protein degradation with photocaged protacs. *Journal of the American Chemical Society*, 141(46):18370–18374, 2019.

[28] Ashton C Lai and Craig M Crews. Induced protein degradation: an emerging drug discovery paradigm. *Nature reviews Drug discovery*, 16(2):101–114, 2017.

[29] Radosław P Nowak, Stephen L DeAngelo, Dennis Buckley, Zhixiang He, Katherine A Donovan, Jian An, Nozhat Safaee, Mark P Jedrychowski, Charles M Ponthier, Mette Ishoey, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. *Nature chemical biology*, 14(7):706–714, 2018.

[30] Weijin Wang, Qiuzhi Zhou, Tao Jiang, Shihong Li, Jinwang Ye, Jie Zheng, Xin Wang, Yanchao Liu, Minmin Deng, Dan Ke, et al. A novel small-molecule protac selectively promotes tau clearance to improve cognitive functions in alzheimer-like models. *Theranostics*, 11(11):5279, 2021.

[31] Matthieu Schapira, Matthew F Calabrese, Alex N Bullock, and Craig M Crews. Targeted protein degradation: expanding the toolbox. *Nature reviews Drug discovery*, 18(12):949–963, 2019.

[32] Lucia Wang and Abhishek Sharma. Serds: a case study in targeted protein degradation. *Chemical Society Reviews*, 51(19):8149–8159, 2022.

[33] Kristin M Riching, Elizabeth A Caine, Marjeta Urh, and Danette L Daniels. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. *Chemical Society Reviews*, 51(14):6210–6221, 2022.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.